Available data indicates that: Lower starting doses generally produce fewer GI symptoms Slower titration can reduce discontinuation risk Most side effects occur early and decrease as the body adapts For researchers, this reinforces the importance of understanding how trial dosing strategy influences adverse event frequency , especially when comparing Phase 2 vs Phase 3 outcomes
Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine and trimethylamine-N-oxide, since these metabolites are normally excreted in the urine
Those with seizure disorders require closer oversight, particularly if their neurologist is adjusting medications
[15] Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C
2 Confirm your step-therapy documentation with your neurologist Before starting the PA process, verify with your neurologist or headache specialist that your treatment history prior oral preventives tried, reason for discontinuation, and migraine frequency is well documented
